About AFYX Therapeutics
AFYX Therapeutics is a company based in Copenhagen (Denmark) founded in 2013.. AFYX Therapeutics has raised $33.34 million across 6 funding rounds from investors including European Union, Novoseeds and EIC Fund. The company has 1 employees as of January 31, 2024. AFYX Therapeutics offers products and services including Gefena, Diaphine, and Nimorazole. AFYX Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Copenhagen, Denmark
- Employees 1 as on 31 Jan, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Afyx Therapeutics A/S
-
Annual Revenue
-
Net Profit
$-1.22 M (USD)69as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$33.34 M (USD)
in 6 rounds
-
Latest Funding Round
$551.04 K (USD), Grant
Aug 31, 2019
-
Investors
European Union
& 7 more
-
Employee Count
1
as on Jan 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AFYX Therapeutics
AFYX Therapeutics offers a comprehensive portfolio of products and services, including Gefena, Diaphine, and Nimorazole. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tablet used for induction of labor in medical settings.
Product contributing to revenue through sales growth.
Product sold primarily in Norway for medical applications.
Funding Insights of AFYX Therapeutics
AFYX Therapeutics has successfully raised a total of $33.34M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $551.04 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Grant — $551,035
-
First Round
First Round
(30 Sep 2015)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2019 | Amount | Grant - AFYX Therapeutics | Valuation |
investors |
|
| Jun, 2019 | Amount | Series A - AFYX Therapeutics | Valuation | Sofinnova Investments | |
| May, 2019 | Amount | Grant - AFYX Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AFYX Therapeutics
AFYX Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Novoseeds and EIC Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Life science companies are funded through venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AFYX Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AFYX Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Afyx Therapeutics Comparisons
Competitors of AFYX Therapeutics
AFYX Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Afyx Therapeutics
Frequently Asked Questions about AFYX Therapeutics
When was AFYX Therapeutics founded?
AFYX Therapeutics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is AFYX Therapeutics located?
AFYX Therapeutics is headquartered in Copenhagen, Denmark.
Is AFYX Therapeutics a funded company?
AFYX Therapeutics is a funded company, having raised a total of $33.34M across 6 funding rounds to date. The company's 1st funding round was a Grant of $56K, raised on Sep 30, 2015.
How many employees does AFYX Therapeutics have?
As of Jan 31, 2024, the latest employee count at AFYX Therapeutics is 1.
What does AFYX Therapeutics do?
AFYX Therapeutics was founded in 2013 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing self-adhesive drug patches, such as Rivelin, for uniform delivery of therapies to mucosal linings. A pipeline of targeted treatments is advanced for oral health conditions, including Head and Neck Cancer and Oral Lichen Planus, addressing unmet needs in mucosal diseases. Operations center on innovative delivery systems for these applications.
Who are the top competitors of AFYX Therapeutics?
AFYX Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
What products or services does AFYX Therapeutics offer?
AFYX Therapeutics offers Gefena, Diaphine, and Nimorazole.
Who are AFYX Therapeutics's investors?
AFYX Therapeutics has 8 investors. Key investors include European Union, Novoseeds, EIC Fund, Sofinnova, and Lundbeck Foundation.
What is AFYX Therapeutics's valuation?
The valuation of AFYX Therapeutics is $26.56M as of Apr 2017.